Shanghai OPM Biosciences (SH:688293) Sou Hu Cai Jing·2025-10-27 02:57Group 1 - The "Shengyan Wanwu" Biomanufacturing Industry Value Partner Conference was held in Shanghai, where the first biomanufacturing industry fund in Shanghai was launched [1] - The fund is initiated by Daotong Investment and Aopumai, utilizing a "C (main industry chain enterprise) + VC (professional investment institution)" dual-driven model [1] - Aopumai, a leading company in cell culture media, and Daotong Investment, with experience in early-stage medical and synthetic biology investments, aim to integrate resources from enterprises, universities, and research institutions to promote technological breakthroughs and industry ecosystem development [1] Group 2 - Aopumai's Chairman, Xiao Zhihua, stated that the collaboration aims to merge Aopumai's industry experience with Daotong's investment expertise to discover and support "tomorrow's stars" in the biomanufacturing industry chain [3] - Aopumai, established in 2013 and listed on the Sci-Tech Innovation Board in 2022, specializes in providing cell culture solutions and end-to-end CDMO services, with over 18,000 square meters of GMP-compliant production facilities [3] - Daotong Investment, founded in 2015, focuses on early-stage investments and industry mergers in the life sciences sector, covering various investment opportunities in medical equipment, biotechnology, and other related fields [3]